China has basically completed formulation of the 13th Five-Year Plan (2016-2020) for bio-pharmaceutical industry and will officially unveil it in the second half of 2016, the Xinhua-run newspaper Economic Information Daily reported on July 4.
According to the plan quoted by the newspaper, the country's bio-pharmaceutical industry will give priority to developing medicines for major diseases, biotech medicines, new vaccines and cell therapy preparations, as well as major medical technology like 3D printing.
Except for making detailed deploy on the research and development (R&D) of medicine, the plan has also called for an international development of the whole industry. By 2020, China will try to make the medicine quality of a large number of bio-pharmaceutical enterprises get in line with international standard and at least 100 pharmaceutical preparation enterprises obtain the authentication of American, European, Japanese countries and World Health Organization (WHO).
Meanwhile, based on international medicine standard, China will promote 10-20 chemical medicines and high-end preparations, 3-5 traditional Chinese medicines, 3-5 bio-tech medicines to complete registration in American and European countries, and accelerate the pace to get access to the international market.
China boasts a huge bio-pharmaceutical market. At present, it is the second largest medical consumption market, with net sales volume of medicines in 2014 exceeding 1.5 trillion yuan.
However, the industry is relatively weak in independent R&D. Hence, it is crucial to improve the competitiveness of the industry, disclosed an insider.
Latest comments